Von Hippel-Lindau syndrome: A pleomorphic condition

Cancer

Volumn 86, Issue 8 SUPPL., 1999, Pages 1658-1662

  Friedrich, Christopher A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer genetics; Genetic counseling; Medical genetics; Medical oncology; Molecular diagnosis; Presymptomatic diagnosis; Von Hippel Lindau syndrome

Indexed keywords

CANCER GENETICS; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE LOCUS; GENE MAPPING; GENE SEQUENCE; GENETIC COUNSELING; HUMAN; LIFE EXPECTANCY; MISSENSE MUTATION; MOLECULAR GENETICS; ONCOLOGY; PRIORITY JOURNAL; PROGNOSIS; VON HIPPEL LINDAU DISEASE;

EID: 0033569787     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19991015)86:8+<1658::aid-cncr4>3.0.co;2-i     Document Type: Conference Paper

References (39)

1. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 1991;28:443-7.
2. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA 1995;273:564-70.
3. Maher ER, Kaelin G Jr., Von Hippel-Lindau disease [Reviews in molecular medicine]. Medicine (Baltimore) 1997;76:381-91.
4. Neumann HPH, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 1991;337:1052-4.
5. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-63.
6. Glenn GM, Choyke PL, Zbar BH, Linehan WM. Von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol 1990;4:312-30.
7. Filling-Katz MR, Choyke PL, Oldfleld E, Charnas L, Patronas NJ, et al. Central nervous system involvement in von Hippel Lindau disease. Neurology 1991;41:41-6.
8. Neumann HP, Eggert HR, Scheremet R, Schumacher M, Mohadjer M, Wakhloo AK, et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 1992;55:898-901.
9. Martz CH. Von Hippel-Lindau disease: a genetic condition predisposing tumor formation. Oncol Nurs Forum 1991;18: 545-51.
10. Maddock I, Moran A, Maher E, Teare M, Norman A, Payne S, et al. A genetic register for von Hippel-Lindau disease. J Med Genet 1996;33:120-7.
11. Melmon K, Rosen S. Lindau's disease. Am J Med 1964;36: 595-617.
12. Seizinger B, Smith D, Filling-Katz M, Neumann H, Green J, Choyke P, et al. Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of von Hippel-Lindau disease. Proc Natl Acad Sci USA 1991:88:2864-8.
13. Latif F, Tory K, Gnarra J, Yao M, Dun FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
14. Richard S, Chauveau D, Chretien Y, et al. Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol Necker Hosp 1994;23:1-27.
15. Ginzburg BM, Montenera WJL, Tyndel FJ, Griesman JA, McKlennan MK. Diagnosis of von Hippel-Lindau disease in a patient with blindness resulting from bilateral optic nerve hemangioblastomas. AJR Am J Roentgenol 1992;159:403-5.
16. Choyke PL, Glenn GM, McClennan MW, Patronas NJ, Linehan WM, Zbar B. Von Hippel-Lindau disease: genetic, clinical and imaging features. Radiology 1995;194:629-42.
17. Moore AT, Maher ER, Rosen P, Gregor Z, Bird AC. Ophthalmological screening for von Hippel-Lindau disease. Eye 1991;5:723-8.
18. O'Reilly GV, Rumbaugh CL, Bowens M, Kido DK, Naheedy MH. Supratentorial haemangioblastoma: the diagnostic roles of computed tomography and angiography. Clin Radiol 1980;32:389-92.
19. Kovacs G, Ishikawa I. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993;22:135-9.
20. Steinbach F, Novick A, Zincke H, Miller D, Williams R, Lund G, et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol 1995;153:1812-6.
21. Walther M, Choyke P, Weiss G, Manolatos C, Long J, Reiter R, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 1995;153:913-6.
22. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-9.
23. Yao M, Latif F, Kuzmin I, Stackhouse T, Zhou FW, et al. Von Hippel-Lindau disease: identification of deletion mutations by pulsed field gel electrophoresis. Hum Genet 1993;92:605-14.
24. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-9.
25. Prowse A, Webster A, Richards F, Richard S, Olschwang S, Resche F, et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997; 60: 765-71.
26. Tory K, Brauch H, Linehan M., et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989;81:1097-1101.
27. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91: 9700-4.
28. Duan DR, Humphrey JS, Chen DYT, Weng Y, Sukegawa J, Lee S, et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 1995;92:6495-99.
29. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
30. Duan DR, Pause A, Burgress W, Aso T, Chen DYT, Garrett KP, et al. Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
31. Kibel A, Iliopoulos O, DeCaprio JD, Kaelin WG. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995;269:1444-6.
32. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res 1995;55:4544-8.
33. Gnarra JR, Zhou S, Merrill MJ, Wagner J, Krumm A, Papavassiliou E, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci USA 1996;93:10589-94.
34. Glenn GM, Linehan WM, Hosoe S, Latif F, Yao M, Choyke P, et al. Screening for von Hippel-Lindau disease by DNA-polymorphism analysis. JAMA 1992;267:1226-31.
35. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-8.
36. Lamiell J, Salazar F, Hsia Y. Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989;68:1-29.
37. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
38. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, et al. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe and Japan. Hum Mutat 1996;8:348-57.
39. Langsley DG, Wolton RV, Goodman TA. A family with a hereditary fatal disease: psychological studies of a family with Lindau's disease. Arch Gen Psychiatry 1964;10:647-52.